I think there is skepticism about enrollment in the RSV trial Also recent ABUS data doesn’t help Now covid seems to have less of a need for an antiviral in a few years I still think enough irons in the fire to get a hit. And most of the opportunities they are going after are huge so that alone might garner large pharma interest even before the finish line IMO
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.